Interferon β therapy increases serum ferritin levels in patients with relapsing-remitting multiple sclerosis

被引:7
|
作者
Sena, A. [1 ,2 ]
Pedrosa, R. [2 ]
Ferret-Sena, V. [3 ]
Cascais, M. J. [1 ]
Roque, R. [2 ]
Araujo, C. [2 ]
Couderc, R. [4 ]
机构
[1] Univ Nova Lisboa, Fac Ciercias Med, Dept Bioquim, P-1200 Lisbon, Portugal
[2] Hosp Capuchos, Serv Neurol, Lisbon, Portugal
[3] Cooperat Egas Moniz, Dept Fisiol, Monte De Caparica, Portugal
[4] Hop Trousseau, AP HP, Biochim Lab, F-75571 Paris, France
来源
MULTIPLE SCLEROSIS | 2008年 / 14卷 / 06期
关键词
multiple sclerosis; ferritin; iron metabolism; interferon beta;
D O I
10.1177/1352458508089687
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Serum ferritin levels have been found to be increased in patients with active progressive multiple sclerosis (MS). However, its levels are reported to be unchanged in stable and in active relapsing-remitting (RR) form of the disease. No research to date has assessed the influence of interferon beta (IFN-beta) on ferritin concentrations. In this study, serum ferritin levels were measured in 43 individuals with RR- MS and 38 age- and sex- matched control volunteers. There were no significant differences between controls and patients under stable and untreated conditions. In patients at 12 months after the beginning of IFN-beta therapy, ferritin levels were higher in women and in men, in comparison with baseline (71.4 +/- 58.6 vs 43.4 +/- 29.9 ng/mL, P = 0.0006 and 216.0 +/- 124.3 vs 127.8 +/- 74.9 ng/mL, P = 0.0022, respectively). These results suggest that larger prospective studies are required to evaluate the role of serum ferritin in MS and its potential usefulness in monitoring responses to immunomodulatory therapies.
引用
收藏
页码:857 / 859
页数:3
相关论文
共 50 条
  • [11] Is interferon effective and safe for relapsing-remitting multiple sclerosis?
    Filippini, G
    Incorvaia, B
    NEUROEPIDEMIOLOGY, 2002, 21 (06) : 310 - 310
  • [12] Defining the response to interferon-β in relapsing-remitting multiple sclerosis patients
    Río, J
    Nos, C
    Tintoré, M
    Téllez, N
    Galán, I
    Pelayo, R
    Comabella, M
    Montalban, X
    ANNALS OF NEUROLOGY, 2006, 59 (02) : 344 - 352
  • [13] Circuit class therapy in patients with relapsing-remitting multiple sclerosis
    Kolcava, J.
    Kocica, J.
    Musilova, M.
    Dosbaba, F.
    Kratochvilova, J.
    Krizova, D.
    Stourac, P.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 633 - 634
  • [14] Clinical characteristics of nonresponders to interferon beta therapy for relapsing-remitting multiple sclerosis
    Waubant, E
    Vukusic, S
    Confavreux, C
    NEUROLOGY, 2002, 58 (07) : A189 - A190
  • [15] Long-term adherence to interferon β therapy in relapsing-remitting multiple sclerosis
    Portaccio, E.
    Zipoli, V.
    Siracusa, G.
    Sorbi, S.
    Amato, M. P.
    EUROPEAN NEUROLOGY, 2008, 59 (3-4) : 131 - 135
  • [16] Clinical predictors of response to interferon-β therapy in relapsing-remitting multiple sclerosis
    Portaccio, E
    Zipoli, V
    Siracusa, G
    Sorbi, S
    Amato, MP
    MULTIPLE SCLEROSIS, 2004, 10 (7032): : S237 - S238
  • [17] Serum uric acid level in patients with relapsing-remitting multiple sclerosis
    Ashtari, Fereshteh
    Bahar, Mohammadali
    Aghaei, Maryam
    Zahed, Arash
    JOURNAL OF CLINICAL NEUROSCIENCE, 2013, 20 (05) : 676 - 678
  • [19] Relapsing-remitting multiple sclerosis
    Flores, A
    Ochoa, E
    Zamora, S
    Barrientos, UN
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2003, 214 (1-2) : 110 - 110
  • [20] Interferon beta-1a in relapsing-remitting multiple sclerosis
    Blumhardt, L
    HOSPITAL MEDICINE, 1999, 60 (03): : 192 - 195